• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Once-daily oral treatment for your adult patients with moderate to severe rheumatoid arthritis1

      One dose, one tablet, once a day

      Starting patients on RINVOQ

      A convenient guide providing information on dosing, screening, monitoring and safety recommendations.

      Dosing recommendations1

      • The recommended dose of RINVOQ is one 15-mg tablet once a day, with or without food
      • Tablets should be swallowed whole, and should not be split, crushed, or chewed
      • RINVOQ may be taken at any time of the day; patients may find it easier to take RINVOQ at the same time every day to help them remember to take it

      RINVOQ can be taken as monotherapy or in combination with methotrexate. Overall, clinical response rates were consistent across patient populations, with or without methotrexate.2,3

      Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.

      I want to find out more about RINVOQ

      I want to receive more information about RINVOQ

      Reference

      1. RINVOQ (Upadacitinib) SmPC.
      2. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT MONOTHERAPY) a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303-2311. doi:10.1016/S0140-6736(19)30419-2
      3. Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response [published online July 30, 2019]. Ann Rheum Dis. doi:10.1136/annrheumdis-2019-215764

      UK-UPAD-220091. Date of preparation: March 2022

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com